Cell And Gene Therapies Require Highly Specialized Formulation And Manufacturing Capabilities

By Dr. Maaike Everts, Technical Marketing Leader, Parenteral Drug Delivery, Evonik

Recent improvements in our understanding of the human genome, together with advanced DNA editing and analytical tools, position the cell and gene therapy market for explosive growth over the coming decade. However, these technologies have significant formulation development, cGMP manufacturing and aseptic filling challenges, which must all be overcome before this potential can be fully commercialized. The engagement of a CDMO partner with a broad portfolio of delivery technologies, a strong formulation track record and manufacturing flexibility is the preferred pathway for success within this highly specialized area.